Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal and remain at increased risk of cardiovascular events1 First-in-class siRNA biological mechanism enables unique twice-yearly, subcutaneous dosing regimen and seamless integration into […]
Tag: Novartis
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated reduced risk in total heart failure hospitalizations and cardiovascular death in women, compared to men2 Among patients who had been previously hospitalized, those who were screened during or […]
Blackstone Life Sciences and Novartis Launch Anthos Therapeutics to Develop Innovative Medicines for Cardiovascular Disease
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Blackstone Life Sciences today announced the launch of Anthos Therapeutics Inc. (“Anthos”), a new biopharmaceutical company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients. As part of this launch, Novartis has licensed to Anthos MAA868, an antibody directed at Factor XI and XIa, key components of […]
Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)
Basel, February 25, 2019 – Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy. TQJ230 was discovered by Ionis and has been co-developed to […]
Recent
Heartflow Unveils Bold New Vision for Management of Coronary Artery Disease
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
Enhancing radiology workflows: Sectra and Siemens Healthineers enable seamless integration across systems for better patient care
Popular
- No commented posts yet